Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

AIDS Malignancy Consortium (Other)
Overall Status
Not yet recruiting ID
National Cancer Institute (NCI) (NIH)

Study Details

Study Description

Brief Summary

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Anticipated Enrollment :
130 participants
Intervention Model:
Parallel Assignment
None (Open Label)
Primary Purpose:
Official Title:
A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2027
Anticipated Study Completion Date :
Sep 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Pegylated Liposomal Doxorubicin

Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.

Drug: Pegylated liposomal doxorubicin
PLD 20 mg/m2 on Day 1 of every 21-day cycle
Other Names:
  • Doxil
  • Active Comparator: Paclitaxel

    Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.

    Drug: Paclitaxel
    PTX 100 mg/m2 on Day 1 of every 21-day cycle
    Other Names:
  • Taxol
  • Outcome Measures

    Primary Outcome Measures

    1. Progression Free Survival at 48 weeks [48 weeks]

      Progression free survival (PFS) is defined as the length of time from enrollment into the study until disease progression or death. Disease progression will be assessed using the Kaposi Sarcoma Response Evaluation Criteria. Progressive disease is defined as: 1) 25% increase in the sum of perpendicular diameters of the indicator lesions; 2) 25% increase in the total number of KS lesions or the appearance of 5 new lesions; OR 3) 25% increase in the number of raised lesions

    Secondary Outcome Measures

    1. Frequency and severity of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in participants receiving PLD or PTX. [96 weeks]

      The frequency of adverse events that occur in patients receiving PLD will be compared with the frequency of adverse events in patients receiving PTX

    2. Objective response rate for AIDS-related KS in patients receiving PLD and PTX [96 weeks]

      The objective response rate is defined as the sum of the number of complete and partial responses in patients receiving PLD or PTX.

    3. Duration of Response in patients receiving PLD and PTX [96 weeks]

      Response duration is defined as the time from first documentation of complete or partial response as measured by KS response criteria to the documentation of first progression of disease as measured by KS response criteria

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    1. HIV-1 infection.

    2. Histologically confirmed KS at any time prior to study entry, confirmed by an AIDS Malignancy Consortium (AMC)-certified pathologist.

    3. Current stage T1 KS (irrespective of prior treatment with antiretroviral therapy (ART) OR

    Stage T0 KS that has progressed or not responded after a minimum of 12 weeks of treatment with ART. Participants with T0 KS must have either:

    • 20 or more skin and/or oral KS lesions, and/or

    • any number of lesions on exposed body areas that have an adverse effect on quality of life (e.g., stigmatization).

    1. Men and women ≥ 18 years. Because no dosing or adverse event data are currently available on the use of PTX or PLD for AIDS-KS in persons <18 years of age, children are excluded from this study

    2. Karnofsky performance status ≥ 60 (ECOG ≤ 2).

    3. Echocardiogram or Multiple gated acquisition scanning (MUGA) showing an ejection fraction ≥ 50%.

    4. Ability and willingness of participant or legal guardian to provide informed consent.

    5. Participants may be ART-naïve or ART-experienced but must be able to receive an ART regimen considered likely to result in HIV suppression.

    6. Measurable cutaneous KS, defined as follows:

    • When available, a minimum of five bi-dimensionally measurable KS cutaneous marker lesions.

    • If fewer than five bi-dimensionally measurable marker lesions are available, the total surface area of the marker lesion(s) must be ≥ 700mm2.

    1. The following laboratory values obtained within 14 days prior to study entry:
    • Absolute Neutrophil Count ≥ 1000 cells/mm3.

    • Hemoglobin ≥ 8 g/dL (may be achieved with transfusion if clinically indicated, in the opinion of the investigator).

    • Platelet count ≥ 75,000/mm3.

    • ALT, AST, Alkaline phosphatase < 5 × upper limit of normal (ULN).

    • Total bilirubin: ≤ 1.5 × ULN, unless the participant is receiving an antiretroviral drug known to be associated with increased bilirubin, in which case the direct fraction should be ≤ 2 x the ULN.

    • Creatinine < institutional ULN OR estimated glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

    1. Women of reproductive potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months), must have a negative pregnancy test done within 24 hours of initiating the protocol-specified chemotherapy medication.

    2. Participants must agree to use two reliable forms of contraception simultaneously while receiving study protocol-specified medication and for 6 months after stopping the medication.

    3. Adequate venous access.

    4. No prior chemotherapy or use of systemic cytotoxic therapy agents.

    5. Participant is able to understand and willing to sign a written informed consent document.

    Exclusion Criteria:
    1. Current acute, chronic, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy before study entry and/or is not clinically stable.

    2. Serious illness necessitating hospitalization/systemic treatment within 14 days prior to study entry

    3. Breastfeeding or pregnant women are excluded because of potential risks of cytotoxic chemotherapy to an unborn child or infant.

    4. Known history of congestive heart failure and/or systolic ejection fraction < 50%.

    5. Prior radiotherapy to KS indicator lesions

    6. Prior or current immunotherapy

    7. Any immunomodulator, HIV vaccine, live attenuated vaccine, other investigational vaccine within 30 days prior to study entry, excluding vaccines against COVID-19/SARS-CoV-2, which are permitted.

    8. Known allergy/hypersensitivity to the study drug or its formulation

    9. Any condition, including the presence of laboratory abnormalities, which in the opinion of the responsible investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.

    10. Corticosteroid use at doses above those given for replacement therapy for adrenal insufficiency within the last 30 days prior to study entry.

    11. Patients with psychiatric illness and/or social circumstances that would limit compliance with study requirements.

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • AIDS Malignancy Consortium
    • National Cancer Institute (NCI)


    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    AIDS Malignancy Consortium Identifier:
    Other Study ID Numbers:
    • AMC-114
    • U01CA121947
    First Posted:
    Jun 9, 2022
    Last Update Posted:
    Jul 21, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Product Manufactured in and Exported from the U.S.:
    Keywords provided by AIDS Malignancy Consortium
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2022